



SpeedX adds Biosapientia to Distribution Network

Partnership with Biosapientia expands SpeedX product availability in France

SYDNEY, AUSTRALIA – (May 17, 2023). SpeedX have announced signing a new distribution partner, further extending access for customers to market leading SpeedX **ResistancePlus**[®] and **PlexPCR**[®] tests. Biosapientia will distribute SpeedX **ResistancePlus**[®] MG and **ResistancePlus**[®] GC tests across the public hospital system, buying groups, and independent private laboratories throughout France.

“We continue to see demand for our key tests and technology around the world,” says Warwick Need, SpeedX Director of Sales. “Biosapientia are a great fit for SpeedX products, and we are looking forward to working with them to expand reach into more French laboratories, giving them the opportunity to provide **ResistancePlus**[®] tests and support the use of Resistance Guided Therapy (RGT) with their clinician partners.”

Guidelines for management of infectious diseases are moving away from empiric treatment pathways towards more directed use of antibiotics. Following RGT practices can positively impact patient cure rates while reducing overall healthcare costs.

“We are thrilled to partner with Biosapientia — delivering innovative clinical diagnostics and improve patient outcomes”, Need said.

“France is the 4th largest consumer of antibiotics in Europe according to ESAC-Net monitoring data” declares Franck Catteau, President of Biosapientia.

“Antibiotic resistance is the cause of more than 5,000 deaths per year in patients with infections caused by resistant bacteria and 125,000 patients develop an infection linked to resistant bacteria. The fight against antibiotic resistance has become a major public health issue in France and a growing number of molecular biology tests for the detection of antibiotic resistance mutations are now being fully reimbursed by the social security system.

The **ResistancePlus**[®] tests from SpeedX represent essential diagnostic tools to guide the clinicians in delivering the most appropriate treatment to their patients and perfectly complement our range of molecular diagnostic solutions.” Catteau said

In addition to **ResistancePlus**[®] MG* — simultaneously detecting *Mycoplasma genitalium* and genetic markers for azithromycin resistance and **ResistancePlus**[®] GC* — combining *Neisseria gonorrhoeae* (GC) detection with markers for ciprofloxacin susceptibility, the SpeedX sexual health portfolio also includes **PlexPCR**[®] VHS — a multiplex test for herpes simplex virus (1 and 2), varicella zoster and *Treponema pallidum* (syphilis).

*Not available in the U.S.

About SpeedX Pty Ltd

Founded in 2009, SpeedX is an Australian-based private company with offices in London and the US, and distributors across Europe. SpeedX specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management. Innovative real-time polymerase chain reaction (qPCR) technology has driven market-leading multiplex detection and priming strategies. SpeedX has a portfolio of CE-IVD & IVDR kits for detection of infectious disease pathogens, sexually transmitted infection (STI), and antimicrobial resistance markers.

SpeedX **ResistancePlus**[®] tests enable Resistance Guided Therapy, improving patient outcomes by empowering practitioners to make informed clinical decisions.

For more information about SpeedX please see: <http://plexpcr.com>

About Biosapientia

Founded in 2020, BIOSAPIENTIA is a French company specialized in the distribution of *in vitro* diagnostic solutions for clinical laboratories. The company supplies automated equipments and molecular biology reagents to the French laboratories, offering a large portfolio of PCR tests for the screening and monitoring of a wide range of pathogenic infectious agents and the detection of genetic mutations of interest in the following fields of application:

- Sexually transmitted infections
- Quantification of viral load
- Respiratory infections
- Gastrointestinal infections
- Transplantation / Immunocompromised
- Meningitis / Nervous system infections
- Thrombophilic mutations
- Oncohematology
- Pharmacogenetics
- Human Genetics
- Microbiology

For more information about Biosapientia please see: <https://biosapientia.com/>

Contact:

Michelle Howie
Associate Director | Global Strategic Marketing
michelleh@speedx.com.au
+61 499 743 199

PR0055